Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 Combination Therapy in Advanced Non-Small Cell Lung Cancer
NCT07899086Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, randomised, open-label trial of risvutatug rezetecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Dose-Limiting Toxicity at 21 days and Objective Response Rate up to 48 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07899086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07899086.